Publicaciones en colaboración con investigadores/as de Hospital de la Santa Creu i Sant Pau (22)

2024

  1. Cardiac events occurring after allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide. Study conducted on behalf of the GETH-TC

    Bone Marrow Transplantation

  2. Characterization of Chronic Graft-versus-host Disease After Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide: A Study on Behalf of GETH-TC

    Transplantation, Vol. 108, Núm. 10, pp. 2134-2143

  3. Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy

    Frontiers in Oncology, Vol. 14

  4. Real-World Experience with Isavuconazole in Allogeneic Stem Cell Transplantation in Spain

    Transplantation and Cellular Therapy, Vol. 30, Núm. 10, pp. 1033.e1-1033.e8

  5. Upper and/or Lower Respiratory Tract Infection Caused by Human Metapneumovirus After Allogeneic Hematopoietic Stem Cell Transplantation

    Journal of Infectious Diseases, Vol. 229, Núm. 1, pp. 83-94

2023

  1. Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients

    Viruses, Vol. 15, Núm. 10

2022

  1. CT-275 Incidence and Characteristics of Chronic GVHD in Haploidentical Stem-Cell Transplantation With Post-Transplantation Cyclophosfamide: Experience of the Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH-TC)

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S440-S441

2021

  1. Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers

    Transplantation and Cellular Therapy, Vol. 27, Núm. 6, pp. 493.e1-493.e8

  2. Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study

    Bone Marrow Transplantation, Vol. 56, Núm. 8, pp. 1919-1928

  3. Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation: A multicenter study from the Spanish hematopoietic transplantation and cell therapy group

    Transplant Infectious Disease, Vol. 23, Núm. 4

  4. Clinical outcomes of allogeneic hematopoietic stem cell transplant recipients developing Cytomegalovirus DNAemia prior to engraftment

    Bone Marrow Transplantation, Vol. 56, Núm. 6, pp. 1281-1290

  5. Cytomegalovirus DNAemia and risk of mortality in allogeneic hematopoietic stem cell transplantation: Analysis from the Spanish Hematopoietic Transplantation and Cell Therapy Group

    American Journal of Transplantation, Vol. 21, Núm. 1, pp. 258-271

2017

  1. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

  2. Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial

    Biology of Blood and Marrow Transplantation, Vol. 23, Núm. 1, pp. 53-59

2015

  1. Fungal and viral infections after allogeneic hematopoietic transplantation from unrelated donors in adults: Improving outcomes over time

    Bone Marrow Transplantation, Vol. 50, Núm. 2, pp. 274-281

  2. Severe infections after single umbilical cord blood transplantation in adults with or without the co-infusion of CD34+ cells from a third-party donor: Results of a multicenter study from the Grupo Español de Trasplante Hematopoyético (GETH)

    Transplant Infectious Disease, Vol. 17, Núm. 2, pp. 221-233

2014

  1. MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia

    Leukemia

2013

  1. Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML

    Leukemia, Vol. 27, Núm. 11, pp. 2157-2164

  2. Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients

    British Journal of Haematology, Vol. 162, Núm. 4, pp. 474-482

2010

  1. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA study group

    Haematologica, Vol. 95, Núm. 4, pp. 589-596